Saturday, 31 October 2026European Markets

ABG SUNDAL COLLIER And FLOW TRADERS Have A High Dividend Yield And Return On Equity In The Capital Markets Industry.

Loading stream...

(VIANEWS) - ABG SUNDAL COLLIER (ABG.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Capital Markets industry.

Financial Asset Price Forward Dividend Yield Return on Equity
ABG SUNDAL COLLIER (ABG.OL) kr5.80 9.65% 24.73%
FLOW TRADERS (FLOW.AS) €17.16 1.7% 6.07%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ABG SUNDAL COLLIER (ABG.OL)

9.65% Forward Dividend Yield and 24.73% Return On Equity

ABG Sundal Collier Holding ASA, together with its subsidiaries, provides investment banking, stockbroking, and corporate advisory services in Norway, Sweden, Denmark, and internationally. The company offers corporate financing services for corporate clients to raise capital through equity or debt financing. It is also involved in advising companies in relation to mergers, acquisitions, and sales, as well as to various real asset transactions and other advisory services. In addition, the company provides secondary security brokerage and research services. The company was founded in 1984 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ABG SUNDAL COLLIER has a trailing twelve months EPS of kr0.41.

PE Ratio

ABG SUNDAL COLLIER has a trailing twelve months price to earnings ratio of 14.15. Meaning, the purchaser of the share is investing kr14.15 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.73%.

More news about ABG SUNDAL COLLIER.

2. FLOW TRADERS (FLOW.AS)

1.7% Forward Dividend Yield and 6.07% Return On Equity

Flow Traders Ltd. operates as a financial technology-enabled multi-asset class liquidity provider in Europe, the Americas, and Asia. The company provides liquidity support that allows investors to continue to buy or sell exchange traded products or other financial instruments. It offers liquidity through financial products. Flow Traders Ltd. was founded in 2004 and is headquartered in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, FLOW TRADERS has a trailing twelve months EPS of €0.81.

PE Ratio

FLOW TRADERS has a trailing twelve months price to earnings ratio of 21.19. Meaning, the purchaser of the share is investing €21.19 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.07%.

Volume

Today's last reported volume for FLOW TRADERS is 136476 which is 27.68% below its average volume of 188720.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Jun 17, 2024, the estimated forward annual dividend rate is 0.3 and the estimated forward annual dividend yield is 1.7%.

More news about FLOW TRADERS.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com